DeepMind spinout Isomorphic Labs raised $2.1 billion as Demis Hassabis now points to first AI-designed drugs entering human trials by late 2026.
What changed
The company uses IsoDDE, a pipeline combining structure prediction, molecule generation, binding prediction and ADMET assessment.
Thrive, Alphabet-linked funds, MGX, Temasek and a UK sovereign AI fund joined the round, showing the capital intensity of AI drug discovery.
Why it matters
Entering clinical trials is not the same as approval; the pharmaceutical probability game remains slow and harsh.
What to watch
The useful signal is not the headline number alone, but whether the product, contract or platform shift becomes repeatable over the next two quarters.
Sources: CocoLoop